Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
The thinly traded, nano-cap biotech Akari Therapeutics PLC (NASDAQ:AKTX) gap-opened higher Wednesday morning, and shares were advancing strongly on above-average volume.
What Happened
Akari, which focuses on developing therapies for orphan autoimmune and inflammatory diseases, said Wednesday the FDA has granted its nomacopan Fast Track designation for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy, or HSCT-TMA, in pediatric patients.
Why It's Important
HSCT-TMA is an orphan condition with no approved therapy and and an estimated fatality rate of 80%.
The Fast Track designation is issued to facilitate the development and expedite the review of new drugs that show promise in treating serious life-threatening conditions and address unmet medical needs.
The status vests advantages such as frequent communication and meetings with the FDA to review the developmental plan for the drug, including the design of proposed clinical trials, use of biomarkers and the extent of data needed for approval.
If relevant criteria are met, a drug with a Fast Track designation qualifies for a priority review, which reduces the review period from the standard 12 months to six months.
The pivotal trial that could support a regulatory filing is set to commence in the fourth quarter of 2019.
Akari shares were trading higher by 34.25% at $2.43 at the time of publication Wednesday on about 150 times their average volume.
Related Links:
The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering
Lilly's Psoriasis Drug Found Superior To J&J's Tremfya In Phase 4 Study
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!